30 closest matches · ranked by relevance
Nasopharyngeal Nonkeratinizing Carcinoma · Recurrent Nasopharynx Carcinoma · Stage III Nasopharyngeal Carcinoma AJCC v7
Primary: Confirmed Response Rate (Complete Response or Partial Response) Based on RECIST Version 1.1 — 20.5 percentage of patients with a response
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Nasopharyngeal Carcinoma
Primary: 3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy — 100 participants with loco-regional control
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Nasopharyngeal Carcinoma
Primary: Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death — 62; 32; 3; 1 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 · Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Primary: Two Year Event-free Survival (EFS) — 0.87 Estimated probability
Recurrent or Metastatic Nasopharyngeal Cancer
Primary: Progression-free Survival as Assessed by the Independent Review Committee (IRC) — 9.2; 7.4 Months
Recurrent Lymphoepithelioma of the Nasopharynx · Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Lymphoepithelioma of the Nasopharynx
Primary: Clinical Benefit Rate — 54.5 percentage of participants
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
Stage II Lymphoepithelioma of the Nasopharynx · Stage II Squamous Cell Carcinoma of the Nasopharynx · Stage III Lymphoepithelioma of the Nasopharynx
Primary: Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy — 18; 4 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Head and Neck Cancer · Oral Complications of Radiation Therapy · Radiation Toxicity
Primary: Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered — 9 participants
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Nasopharyngeal Neoplasms
Primary: Overall Survival (OS) — 17.2; 15.3 Months — p=0.2262
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Nasopharyngeal Carcinoma
Primary: Objective Response Rate (ORR) Assess by Independent Review Committee (IRC) — 28.3 percentage of participants
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Nasopharyngeal Carcinoma
Primary: Number of Participants With Acute Toxicity — 23 Participants
Recurrent Head and Neck Cancer
Primary: Safety Measures (Adverse Events and Laboratory Parameters) With Repeat Cycles of Treatment. — 5; 0; 8; 8 Participants
Effect of Drugs
Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Primary: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the…
Primary Mediastinal (Thymic) Large B-Cell Lymphoma · Recurrent Aggressive Non-Hodgkin Lymphoma · Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate of Pembrolizumab With Concurrent Fractionated External Beam Radiotherapy (EBRT) Among Patients With Relapsed and Refractory Non-Hodgkin Lymphoma…
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants